BMJ 2014;348:g1615 26 February 2014
Author: Peter Doshi
“…The greatest concern may be that the current industry framework continues to treat clinical trial data as the property of trial sponsors and not part of an intellectual commons to be maintained and governed by a third party such as a regulator.
But as the access-to-data debate has moved from promises to policies, procedures, and systems designed to facilitate wider access to clinical trial data, the onus to document how well the system is working falls on those requesting data…”
Find article here.